Table 2.
Patients Enrolled in the Feasibility Study
| Pat No. | Gender | Age (years) | Diagnosis | Time since initial diagnosis (months) | Molecular target | Targeted therapy | Time period targeted therapy (months) | Number of prior targeted therapies (months) | Initial ECOG | Initial KPS | Months TRACE app used | End of study reached (usage app ≥ 6 months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 01 | Female | 57 | Gallbladder carcinoma | 26.1 | FGFR2— KIIAA1598 | FGFR inhibitor (Pemigatinib) | 2 | 0 | 0 | 90 | 7.2 | Yes |
| 02 | Female | 34 | Spinal ependymoma, CNS WHO grade 3 | 9.6 | NF2 | mTOR inhibitor (Everolimus) | ONG | 0 | 2 | 70 | 5.1** | Yes |
| 03 | Female | 61 | Melanoma | 72.5 | CDKN2A, CDK4, CDK6, CCND2 | CDK4/6 Inhibitor (Palbociclib) | 1 | 1 (4) | 1 | 80 | 11.9 | Yes |
| 04 | Male | 33 | Diffuse midline glioma, CNS WHO grade 4 | 30.1 | NF1 | MEK inhibitor (Trametinib) | ONG | 1 (7.1) | 1 | 90 | 7.0 | Yes |
| 05 | Female | 48 | High-grade astrocytoma with piloid features | 16.7 | NF1 | MEK inhibitor (Trametinib, Selumetinib) | ONG | 1 (6.5) | 2 | 60 | 8.1 | Yes |
| 06 | Male | 33 | Glioblastoma, IDH wildtype, CNS WHO grade 4 | 90.6 | EGFR | Tyrosine kinase inhibitor (Afatinib) | 1 | 0 | 2 | 60 | 1.1 | No, due to disease progression |
| 07 | Female | 61 | Gallbladder carcinoma | 30.6 | FGFR2—BICC1 | FGFR inhibitor (Pemigatinib, Lenvatinib) | ONG | 1 (16.7) | 1 | 80 | 13.3 | Yes |
| 08 | Female | 34 | Pineal parenchymal tumor of intermediate differentiation, CNS WHO grade 2 | 273.3 | DICER1 | Nortiptyllin/ Gemcitabine |
2 | 0 | 1 | 70 | 1.1 | No, due to disease pro-gression |
| 09 | Male | 28 | Astrocytoma, IDH-mutant, CNS WHO grade 2 | 73 | IDH1 | IDH inhibitor (Ivosidenib) | 4.6 | 0 | 1 | 80 | 5.3** | Yes |
| 10 | Female | 70 | Gallbladder carcinoma | 42.4 | FGFR2—RBFOX2 | FGFR inhibitor (Pemigatinib) | ONG | 0 | 1 | 80 | 7.2 | Yes |
| 11 | Male | 55 | Meningioma, CNS WHO grade 2 | 209 | NF2 | mTOR (Everolimus) | ONG | 0 | 1 | 70 | 2.6 | No, due to clinical deterioration1 |
| 12 | Female | 32 | Papillary tumor of the pineal region WHO grade 2 | 48.4 | NF2, PTEN | mTOR inhibitor (Everolimus) | ONG | 0 | 0 | 90 | 6.3 | Yes |
| 13 | Female | 67 | Oligodendroglioma, CNS WHO grade 2 | 130.8 | IDH1 | IDH inhibitor (Ivosidenib) | n/a | 0 | 2 | 60 | 0 | Disease pro-gression |
| 14 | Male | 59 | Meningioma, CNS WHO grade 2 | 92.2 | NF2 | mTOR inhibitor (Everolimus) | n/a | 0 | 1 | 80 | 0 | No longer interested |
1The caregiver of the patient was interviewed.
Gray-shaded fields indicate patients (2) who gave informed consent to the study but did not start using the app.
Abbreviations: KPS = Karnofsky Performance Status, ONG = ongoing.
**The patient started the app in July 2022, due to data cut-off in 12/2022, the 6 months were not reached.